Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The findings of two studies, published in The Lancet Infectious Diseases journal, reveal that by 2016–2018 malaria parasites resistant to both artemisinin and its widely used partner drug piperaquine represented more than 80% of the parasites circulating in northeast Thailand and Vietnam, despite having only emerged in western Cambodia in 2008.

Mosquito © CDC James Gathany

23 July 2019 Bangkok (Thailand) – A rapidly evolving multi-drug resistant lineage of P. falciparum malaria parasites continues to spread in Southeast Asia, leading to alarmingly high treatment failure rates in Cambodia, Thailand and Vietnam for DHA-piperaquine, one of the world’s most important anti-malaria drugs, say University of Oxford researchers in a study published today in The Lancet Infectious Diseases.

Malaria maps: before 20122 and after 2016DHA-piperaquine should no longer be used to treat falciparum malaria in Cambodia, Vietnam and northeast Thailand as it is ineffective and thereby contributes to increased malaria transmission, according to the author of the study, which was funded with support from the: United Kingdom Department for International Development, UK (DfID); Wellcome Trust, UK; Bill & 78 Melinda Gates Foundation, USA; Medical Research Council, UK; and the National Institute of Health, USA.

The researchers called for urgent action to eliminate falciparum malaria from the Greater Mekong Subregion to prevent local increase of these multiple resistant strains and their further spread to other parts of Asia and Africa and avoid a potential global health emergency.

"Resistance to our antimalarial drugs is worsening and spreading  in the eastern Greater Mekong Subregion," said study co-author University of Oxford Prof Sir Nick White. “We need urgently to eliminate malaria in this region and act now to prevent the spread of these multi-drug resistant parasites to other parts of Asia and Sub-Saharan Africa. When resistance to previous antimalarial drugs arose in Southeast Asia and spread to Africa-millions of children died as a consequence.”

Malaria deaths dropped significantly after the introduction in the late 1990s of artemisinin-combination therapy (ACT) – where artemisinin, our most effective drug against malaria –  is combined with another anti-malaria drug such as piperaquine.

However, in 2014, the Tracking Resistance to Artemisinin Collaboration (TRAC) study reported in the New England Journal of Medicine (NEJM) that artemisinin resistance in Plasmodium falciparum – the most deadly form of malaria-causing parasite and the one most prevalent in Africa and Asia – was widespread across the Greater Mekong Subregion.

Since then, global progress against malaria has stalled. Indeed case numbers globally have risen steadily for the past three years, with an estimated 219 million malaria cases (up from 217m in 2016) and 435,000 related deaths in 2017, most of them children under the age of 5 five in sub-Saharan Africa, according to the WHO World Malaria Report 2018.

“DHA-piperaquine is failing and should no longer be used to treat falciparum malaria across the eastern Greater Mekong Subregion. It provides ineffective treatment for the patient and thereby contributes to increased malaria transmission. This has immediate public health importance, so we felt we should not wait to report this until we published our full TRAC II results later this year," said University of Oxford Prof Arjen Dondorp, study co-author and Deputy Director of the Bangkok-based Mahidol Oxford Tropical Medicine Research Unit (MORU).

DHA-piperaquine is an oral artemisinin combination treatment (ACT) medication that is on the WHO’s List of Essential Medicines. DHA-piperaquine is used to treat P. falciparum and P. vivax malaria in Africa and Asia and in large-scale pilot programmes to eliminate malaria in the Greater Mekong Subregion. 

Although there are as yet no reports of artemisinin resistance in Africa, researchers urge elimination of these highly drug-resistant P. falciparum parasites in Southeast Asia to preserve the effectiveness of DHA-piperaquine and other ACTs in Africa and elsewhere in Asia and so prevent a global health emergency.

“Southeast Asia is the cradle of antimalarial drug resistance. We must eliminate falciparum malaria before it becomes untreatable in the Greater Mekong Subregion and elsewhere in Asia. This is the third time that the P. falciparum parasite has developed resistance on a large scale to antimalarial drugs: First, chloroquine and sulphadoxine-pyrimethamine arose and spread in the 60s and 70s, and now resistance has emerged to artemisinins and ACT partner drugs. We must get rid of these parasites once and for all,” said study co-author Dr Rob van der Pluijm, TRAC II coordinator.

In a companion paper in The Lancet Infectious Diseases, Wellcome Sanger Institute researchers report that the strain of P. falciparum malaria which has become DHA-piperaquine resistant, which they call KEL1/PLA1, has evolved and spread widely in recent years after it was first found in Cambodia. The parasites have acquired new mutations and have produced an even higher level of resistance, allowing their proliferation and spread across the Greater Mekong Subregion.

“Genetic surveillance data shows that resistant P. falciparum parasites are evolving further, developing new mutations that make them fitter and more resistant, and enabling them to spread regionally, and take over entire parasite populations,” said University of Oxford Prof Olivo Miotto, study co-author and Senior Informatics Fellow at MORU. “We must act quickly to stop the situation getting worse.”

------------

References

Determinants of dihydroartemisinin-piperaquine treatment failure in falciparum malaria in Cambodia, Thailand and Vietnam: a prospective clinical, pharmacological and genetic study. Rob van der Pluijm et al.(2019). The Lancet Infectious Diseases, 22 July 2019. https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(19)30391-3/fulltext

Evolution and expansion of multidrug resistant malaria in Southeast Asia: a genomic epidemiology study.  William Hamilton and Roberto Amato et al. (2019). The Lancet Infectious Diseases, 22 July 2019. https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(19)30392-5/fulltext

Commentary

Accelerated evolution and spread of multidrug-resistant Plasmodium falciparum takes down the latest first-line antimalarial drug in southeast Asia. Didier Ménard and David A Fidock (2019). The Lancet Infectious Diseases. https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(19)30394-9/fulltext

Notes for editors

Mahidol Oxford Tropical Medicine Research Unit (MORU, www.tropmedres.ac, @MORUBKK) is a research collaboration between Mahidol University (Thailand) and University of Oxford and Wellcome (UK).

The Wellcome Sanger Institute is a world leading genomics research centre that undertakes large-scale research that forms the foundations of knowledge in biology and medicine. Funded by Wellcome, we have the freedom and support to push the boundaries of genomics. Our findings are used to improve health and to understand life on Earth. Find out more at www.sanger.ac.uk or follow us on Twitter, Facebook, LinkedIn and on our Blog

Funders

This research was funded with support from the: United Kingdom Department for International Development, UK; Wellcome Trust, UK; Bill & 78 Melinda Gates Foundation, USA; Medical Research Council, UK; and the National Institute of Health, USA.

Similar stories

World’s largest clinical trial for COVID-19 treatments expands internationally

OCGHR Research

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Tocilizumab reduces deaths in patients hospitalised with COVID-19

OCGHR Research

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that tocilizumab, an anti-inflammatory treatment, reduces the risk of death when given to hospitalised patients with severe COVID-19. The study also showed that tocilizumab shortens the time until patients are successfully discharged from hospital and reduces the need for a mechanical ventilator.

Evidence supports WHO recommendation for primaquine combined with ACTs to block Plasmodium falciparum transmission

OCGHR Publication Research

Evidence from a new study, initiated by the Primaquine Roll Out Group and conducted at WWARN, supports the World Health Organization (WHO) recommendation for use of 0.25mg/kg dose of primaquine (PQ) combined with artemisinin-based combination therapies (ACT) to block Plasmodium falciparum transmission.

Baricitinib to be investigated as a possible treatment for COVID-19 in the RECOVERY trial

OCGHR Research

Baricitinib – an anti-inflammatory treatment for rheumatoid arthritis– is being investigated in the RECOVERY trial, the world’s largest clinical trial of treatments for patients hospitalised with COVID-19, taking place in 177 hospital sites across the UK and with over 33,000 patients recruited so far. As an anti-inflammatory, baricitinib may block the signalling activity of cytokine molecules which contribute to the hyper-inflammatory state seen in severe COVID-19. It is thought that baricitinib may act also have some anti-viral activity. The other treatments currently being investigated in the RECOVERY trial are Regeneron’s antibody cocktail, Aspirin and Colchicine.

Indonesia’s decision to prioritise COVID-19 vaccination to citizens aged 18-59 years old questionable

EOCRU MORU OUCRU

The Indonesian government policy to exclude the elderly in the first phase of the COVID-19 vaccination program could hinder the vaccine’s impact in lowering mortality rates. COVID-19 mortality rates in Indonesia, the highest in Southeast Asia, are dominated by those in the 60 years and above age bracket. In this article published in The Conversation, Kartika Saraswati and fellow DPhil students elaborate how, by prioritising vaccination for elderly, Indonesia may optimally reduce the hospital burden and COVID-19 deaths amidst a limited vaccine supply during the first vaccination phase.

RECOVERY trial closes recruitment to convalescent plasma treatment for patients hospitalised with COVID-19

OCGHR Research

Convalescent plasma has been widely used as a treatment for COVID-19 but to date there has been no convincing evidence of the effect of convalescent plasma on clinical outcomes in patients admitted to hospital with COVID-19. Recruitment to the convalescent plasma arm of the RECOVERY trial has now closed. The preliminary analysis based on 1873 reported deaths among 10,406 randomised patients shows no significant difference in the primary endpoint of 28-day mortality. Recruitment to all other treatment arms – tocilizumab, aspirin, colchicine, and Regeneron’s antibody cocktail – continues as planned.